<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04404517</url>
  </required_header>
  <id_info>
    <org_study_id>IntnsificADA</org_study_id>
    <nct_id>NCT04404517</nct_id>
  </id_info>
  <brief_title>Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks</brief_title>
  <acronym>IntnsificADA</acronym>
  <official_title>Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT to evaluate possible pharmacokinetic differences between the two current regimes of
      intensified adalimumab administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBD patients in need of intensified adalimumab treatment will be randomized to receive 40mg
      sc weekly or 80mg sc every two weeks, and after 6 weeks of treatment each of the groups will
      be allocated to the other dosing regime. Adalimumab blood levels and other features such as
      specific drug antibodies and disease activity parameters will be compared between both
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adalimumab trough level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Drug levels will be measured during 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibodies to Adalimumab (ADA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Antibodies to Adalimumab will be tested for 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response for Ulcerative Colitis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Simple Clinical Colitis Activity Index (SCCAI) (for UC) refers to disease symptoms during the previous week. It is composed of six domains. After recording, the clinician-based SCCAI is able to categorize two types of patients: patients with inactive disease (SCCAI&lt;5) and patients with active disease (SCCAI≥5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response for Ulcerative colitis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Truelove Index (for UC), is composed of 6 variables. Clinical remission was defined as 1 or 2 stools per day without blood, absence of fever or tachycardia, a normal hemoglobin or &quot;returning towards normal,&quot; a normal ESR or &quot;returning towards normal,&quot; and gaining weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response for Crohn´s Disease</measure>
    <time_frame>12 weeks</time_frame>
    <description>Harvey-Bradshaw Index (for CD) considers five parameters. For each parameter a specific score is assigned. A score below 5 is considered as clinical remission. A reduction of 3 points is considered as relevant to define clinical response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fecal calprotectin levels will be tested during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood acute phase reactants</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood acute phase reactants will be tested during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quality of life will be analysed using the Inflammatory Bowel Disease Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment Satisfaction Questionnaire for Medication (TSQM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>40mg1w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab at an administration of 40 mg weekly for 6 weeks, followed by Adalimumab at an administration of 80 mg every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80mg2w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab at an administration of 80 mg every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Monoclonal antibody used in IBD treatment</description>
    <arm_group_label>40mg1w</arm_group_label>
    <arm_group_label>80mg2w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18y

          -  Intensified adalimumab regime at least 4 weeks prior to enrollment.

          -  Immunosuppressants are allowed if a stable dose for &gt; 12w is maintained.

          -  Corticosteroids are allowed if they were initiated prior to enrollment and a stable
             dose is maintained.

        Exclusion Criteria:

          -  Patients unable to understand study protocol, study procedures or not capacitated to
             give informed consent.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Dolores Martin Arranz, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario La Paz. IdiPaz. Universidad Autónoma de Madrid.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Martin Arranz, PhD</last_name>
    <phone>+34912071350</phone>
    <email>emarranz@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Madrd</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Martin Arranz, PhD</last_name>
      <phone>+34912071350</phone>
      <email>emarranz@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario La Paz</investigator_affiliation>
    <investigator_full_name>María Dolores Martín Arranz, PhD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>AntiTNF</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

